Cargando…
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future tri...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436227/ https://www.ncbi.nlm.nih.gov/pubmed/30914057 http://dx.doi.org/10.1186/s13073-019-0631-0 |